References
- Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.
- Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–566.
- Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–115.
- Papp K, Okun M, Vender R. Adalimumab in the treatment of psoriasis: Pooled efficacy and safety results from three pivotal studies. J Cutan Med Surg. 2009;13(suppl 2):S58–66.
- Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: A pooled analysis of randomized clinical trials. Dermatology. 2010;220:1–7.
- Zhang Z, Schmitt J, Wozel G, Kirch W. Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials. Med Klin (Munich). 2009;104:125–136.
- Ardigò M, Giuliani A, de Felice C, Mastroianni A, Berardesca E. Efficacy of adalimumab in plaque psoriasis: Experience on 28 patients. J Drugs Dermatol. 2008;7:935–939.
- Papoutsaki M, Chimeni MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007;57:269–275.
- Van L, Modi SV, Yang DJ, Hsu S. Sustained efficacy and safety of adalimumab in psoriasis treatment: A retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment. Arch Dermatol. 2008;144:804–806.
- Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151(suppl 69):3–15.
- Guenther L, Langley RG, Shear NH, Bissonnette R, Ho V, Lynde C, Integrating biologic agents into management of moderate-to-severe psoriasis: A consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. J Cutan Med Surg. 2004;8:321–327.
- Papp K, Leonardi C, Gordon K, Frevert L. Efficacy and safety of adalimumab in a 120-week open-label extension study in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol. 2007 (suppl February 2007):AB193 (Abstract P2777).
- Rigopoulos D, Gregoriou S, Lazaridou E, Belyayeva E, Apalla Z, Makris M, Treatment of nail psoriasis with adalimumab: An open label unblinded study. J Eur Acad Dermatol Venereol. 2010;24:530–534.
- Ghate JV, Alspaugh CD. Adalimumab in the management of palmoplantar psoriasis. Dermatol Online J. 2009;15:15.
- Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158:549–557.
- Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008;6:75.
- Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: Patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18:25–31.